NO323908B1 - Anvendelse av en prostaglandinlignende forbindelse til fremstilling av et farmasoytisk preparat for behandling av utvortes sekresjonsforstyrrelser, samt forbindelsen 11-dehydroksy-13,14-dihydro-15-keto-16,16-difluor-PGE1 - Google Patents
Anvendelse av en prostaglandinlignende forbindelse til fremstilling av et farmasoytisk preparat for behandling av utvortes sekresjonsforstyrrelser, samt forbindelsen 11-dehydroksy-13,14-dihydro-15-keto-16,16-difluor-PGE1 Download PDFInfo
- Publication number
- NO323908B1 NO323908B1 NO20020133A NO20020133A NO323908B1 NO 323908 B1 NO323908 B1 NO 323908B1 NO 20020133 A NO20020133 A NO 20020133A NO 20020133 A NO20020133 A NO 20020133A NO 323908 B1 NO323908 B1 NO 323908B1
- Authority
- NO
- Norway
- Prior art keywords
- keto
- dihydro
- difluoro
- compound
- use according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 74
- 238000002360 preparation method Methods 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 22
- 230000002997 prostaglandinlike Effects 0.000 title claims description 10
- 229960000711 alprostadil Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003248 secreting effect Effects 0.000 title 1
- 230000028327 secretion Effects 0.000 claims description 81
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 27
- 206010013774 Dry eye Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 206010013781 dry mouth Diseases 0.000 claims description 19
- 208000011580 syndromic disease Diseases 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 208000005946 Xerostomia Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 7
- 229940012356 eye drops Drugs 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 210000000214 mouth Anatomy 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006190 sub-lingual tablet Substances 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
- -1 -isopropyl ester Chemical class 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229960002986 dinoprostone Drugs 0.000 claims description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- FGOJCPKOOGIRPA-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 5-oxoazepane-1,4-dicarboxylate Chemical compound CCOC(=O)C1CCN(C(=O)OC(C)(C)C)CCC1=O FGOJCPKOOGIRPA-UHFFFAOYSA-N 0.000 claims 1
- 235000010357 aspartame Nutrition 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 16
- 210000003296 saliva Anatomy 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000010171 animal model Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 4
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000002638 denervation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 208000005494 xerophthalmia Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000003582 temporal bone Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 206010028665 Myxoedema Diseases 0.000 description 2
- 206010028740 Nasal dryness Diseases 0.000 description 2
- 206010067776 Ocular pemphigoid Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- 206010039390 Salivary gland atrophy Diseases 0.000 description 2
- 206010040628 Sialoadenitis Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 2
- 206010048218 Xeroderma Diseases 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000023652 chronic gastritis Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 208000002169 ectodermal dysplasia Diseases 0.000 description 2
- 208000031068 ectodermal dysplasia syndrome Diseases 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003499 exocrine gland Anatomy 0.000 description 2
- 239000003885 eye ointment Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 150000002373 hemiacetals Chemical class 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000003786 myxedema Diseases 0.000 description 2
- 229940069265 ophthalmic ointment Drugs 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 208000001050 sialadenitis Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 101150020741 Hpgds gene Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036346 Posterior capsule opacification Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004228 maxillary nerve Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000258 minor salivary gland Anatomy 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- VDNLFJGJEQUWRB-UHFFFAOYSA-N rose bengal free acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C21 VDNLFJGJEQUWRB-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003670 sublingual gland Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14362799P | 1999-07-14 | 1999-07-14 | |
| PCT/JP2000/004696 WO2001005388A2 (en) | 1999-07-14 | 2000-07-13 | Use of a fatty derivative for the treatment of external secretiondisorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20020133D0 NO20020133D0 (no) | 2002-01-11 |
| NO20020133L NO20020133L (no) | 2002-03-13 |
| NO323908B1 true NO323908B1 (no) | 2007-07-16 |
Family
ID=22504885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020133A NO323908B1 (no) | 1999-07-14 | 2002-01-11 | Anvendelse av en prostaglandinlignende forbindelse til fremstilling av et farmasoytisk preparat for behandling av utvortes sekresjonsforstyrrelser, samt forbindelsen 11-dehydroksy-13,14-dihydro-15-keto-16,16-difluor-PGE1 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6566398B1 (pt) |
| EP (1) | EP1223925B1 (pt) |
| JP (2) | JP4167828B2 (pt) |
| KR (1) | KR100750553B1 (pt) |
| CN (4) | CN100548977C (pt) |
| AR (2) | AR029381A1 (pt) |
| AT (1) | ATE344027T1 (pt) |
| AU (1) | AU779936B2 (pt) |
| BR (1) | BRPI0012387B1 (pt) |
| CA (1) | CA2377661C (pt) |
| CZ (1) | CZ303958B6 (pt) |
| DE (1) | DE60031710T2 (pt) |
| DK (1) | DK1223925T3 (pt) |
| ES (1) | ES2273706T3 (pt) |
| HK (1) | HK1048443B (pt) |
| HU (1) | HU229318B1 (pt) |
| IL (2) | IL147440A0 (pt) |
| MX (1) | MXPA02000437A (pt) |
| NO (1) | NO323908B1 (pt) |
| PT (1) | PT1223925E (pt) |
| RU (1) | RU2264816C2 (pt) |
| TR (1) | TR200200065T2 (pt) |
| TW (1) | TWI225398B (pt) |
| WO (1) | WO2001005388A2 (pt) |
| ZA (1) | ZA200109726B (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI263505B (en) * | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
| WO2003105823A1 (en) * | 2002-06-14 | 2003-12-24 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth |
| US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| US20040185075A1 (en) | 2003-01-31 | 2004-09-23 | Maria Dalko | Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| FR2850571B1 (fr) * | 2003-01-31 | 2006-07-07 | Oreal | Utilisation d'un derive d'acide(dihydro) jasmonique pour le traitement des peaux seches |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
| US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| JP4249185B2 (ja) | 2003-10-06 | 2009-04-02 | 株式会社オフテクス | 涙液異常の治療のための眼科用組成物 |
| US7923471B2 (en) | 2004-05-14 | 2011-04-12 | Alcon, Inc. | Method of treating dry eye disorders and uveitis |
| US20070265341A1 (en) * | 2004-07-01 | 2007-11-15 | The Schepens Eye Research Institute Inc. | Compositions and methods for treating eye disorders and conditions |
| MX2007000208A (es) * | 2004-07-01 | 2007-08-07 | Schepens Eye Res Inst | Composiciones y metodos para tratar trastornos y condiciones del ojo. |
| DK1841433T3 (da) * | 2005-01-27 | 2012-01-16 | Sucampo Ag | Præparat til behandling af lidelser i centralnervesystemet |
| ATE489955T1 (de) * | 2005-03-04 | 2010-12-15 | Sucampo Ag | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten |
| US7638142B2 (en) * | 2005-10-12 | 2009-12-29 | Vitamin Science, Inc. | Therapeutic composition for the treatment of dry eye syndrome |
| NZ570190A (en) | 2006-01-24 | 2011-03-31 | Sucampo Ag | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| JP2010519177A (ja) * | 2007-02-27 | 2010-06-03 | スキャンポ・アーゲー | ミトコンドリアを保護するための組成物および方法 |
| US9161909B2 (en) | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
| US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
| US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
| US9597278B2 (en) | 2008-11-13 | 2017-03-21 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| US9884082B2 (en) | 2008-11-13 | 2018-02-06 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| EP2389939A1 (en) * | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
| WO2012068247A1 (en) | 2010-11-16 | 2012-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| RU2648474C2 (ru) * | 2011-08-05 | 2018-03-26 | Сукампо Аг | Способ лечения шизофрении |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US8996137B2 (en) | 2013-04-19 | 2015-03-31 | Oculeve, Inc. | Nasal stimulation devices and methods |
| KR20170074926A (ko) * | 2014-10-22 | 2017-06-30 | 오큘레브, 인크. | 안구 건조증을 치료하기 위한 자극 장치 및 방법 |
| WO2017192572A1 (en) | 2016-05-02 | 2017-11-09 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
| JP7300446B2 (ja) | 2018-04-26 | 2023-06-29 | ライオン株式会社 | 外分泌促進剤 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE49783B1 (en) | 1979-05-18 | 1985-12-11 | Efamol Ltd | Pharmaceutical and dietary composition comprising epsilon-linolenic acids |
| GB8319073D0 (en) | 1983-07-14 | 1983-08-17 | Efamol Ltd | Fatty acid compositions |
| JPH0688966B2 (ja) * | 1987-01-28 | 1994-11-09 | 株式会社アールテック・ウエノ | プロスタグランジンｅ類およびそれを含む抗潰瘍剤 |
| JPH07103096B2 (ja) * | 1987-01-28 | 1995-11-08 | 株式会社上野製薬応用研究所 | プロスタグランジンｄ類およびそれを含む鎮静・睡眠剤 |
| DE3711164A1 (de) | 1987-04-02 | 1988-10-20 | Zeiss Carl Fa | Steckelementeinrichtung zur halterung von bauteilen in stapeln |
| CA1324129C (en) * | 1987-04-30 | 1993-11-09 | Ryuzo Ueno | Prostaglandins of the f series |
| JPS63277604A (ja) * | 1987-05-11 | 1988-11-15 | Showa Denko Kk | α−リノレン酸含有化粧料 |
| JPH0692305B2 (ja) * | 1987-05-15 | 1994-11-16 | 株式会社上野製薬応用研究所 | 体温上昇剤 |
| ATE108330T1 (de) | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | Hypotensive okulare mittel. |
| JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体 |
| WO1990001323A1 (en) * | 1988-08-12 | 1990-02-22 | Bernstein Joel E | Method and composition for treating and preventing dry skin disorders |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| TW249226B (pt) * | 1990-04-04 | 1995-06-11 | Aderk Ueno Kk | |
| JPH07100655B2 (ja) * | 1990-04-04 | 1995-11-01 | 株式会社アールテック・ウエノ | 白内障処置剤 |
| ATE174221T1 (de) * | 1990-05-01 | 1998-12-15 | R Tech Ueno Ltd | Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten |
| JPH07113012B2 (ja) * | 1991-01-29 | 1995-12-06 | 株式会社アールテック・ウエノ | 新規１５−ケト−プロスタグランジン類 |
| ATE141794T1 (de) * | 1991-03-14 | 1996-09-15 | R Tech Ueno Ltd | Stimulierung von wundheilung mit 15-keto- prostaglandinverbindungen |
| US5369127A (en) | 1993-04-21 | 1994-11-29 | Allergan, Inc. | 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
| TW420611B (en) * | 1995-03-10 | 2001-02-01 | R Tech Ueno Ltd | Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder |
| US5696166A (en) | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| WO2000038690A2 (en) * | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of dry eye |
| WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| DK1841433T3 (da) * | 2005-01-27 | 2012-01-16 | Sucampo Ag | Præparat til behandling af lidelser i centralnervesystemet |
| ATE489955T1 (de) * | 2005-03-04 | 2010-12-15 | Sucampo Ag | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten |
-
2000
- 2000-07-12 TW TW089113876A patent/TWI225398B/zh not_active IP Right Cessation
- 2000-07-13 CN CNB2006101215152A patent/CN100548977C/zh not_active Expired - Fee Related
- 2000-07-13 DE DE60031710T patent/DE60031710T2/de not_active Expired - Lifetime
- 2000-07-13 BR BRPI0012387A patent/BRPI0012387B1/pt not_active IP Right Cessation
- 2000-07-13 CZ CZ20020133A patent/CZ303958B6/cs not_active IP Right Cessation
- 2000-07-13 CA CA2377661A patent/CA2377661C/en not_active Expired - Lifetime
- 2000-07-13 AT AT00944426T patent/ATE344027T1/de active
- 2000-07-13 EP EP00944426A patent/EP1223925B1/en not_active Expired - Lifetime
- 2000-07-13 DK DK00944426T patent/DK1223925T3/da active
- 2000-07-13 IL IL14744000A patent/IL147440A0/xx unknown
- 2000-07-13 CN CN200910205219A patent/CN101695495A/zh active Pending
- 2000-07-13 US US09/615,703 patent/US6566398B1/en not_active Expired - Lifetime
- 2000-07-13 JP JP2001510445A patent/JP4167828B2/ja not_active Expired - Fee Related
- 2000-07-13 KR KR1020027000471A patent/KR100750553B1/ko active IP Right Grant
- 2000-07-13 CN CN00810238A patent/CN1399548A/zh active Pending
- 2000-07-13 AU AU58533/00A patent/AU779936B2/en not_active Ceased
- 2000-07-13 PT PT00944426T patent/PT1223925E/pt unknown
- 2000-07-13 ES ES00944426T patent/ES2273706T3/es not_active Expired - Lifetime
- 2000-07-13 CN CN2010101574518A patent/CN101829120B/zh not_active Expired - Fee Related
- 2000-07-13 HU HU0202400A patent/HU229318B1/hu not_active IP Right Cessation
- 2000-07-13 TR TR2002/00065T patent/TR200200065T2/xx unknown
- 2000-07-13 MX MXPA02000437A patent/MXPA02000437A/es active IP Right Grant
- 2000-07-13 WO PCT/JP2000/004696 patent/WO2001005388A2/en not_active Application Discontinuation
- 2000-07-13 RU RU2002103597/15A patent/RU2264816C2/ru not_active IP Right Cessation
- 2000-07-14 AR ARP000103635A patent/AR029381A1/es not_active Application Discontinuation
-
2001
- 2001-11-27 ZA ZA200109726A patent/ZA200109726B/en unknown
-
2002
- 2002-01-02 IL IL147440A patent/IL147440A/en active IP Right Grant
- 2002-01-11 NO NO20020133A patent/NO323908B1/no not_active IP Right Cessation
-
2003
- 2003-01-21 HK HK03100518.0A patent/HK1048443B/zh not_active IP Right Cessation
- 2003-03-04 US US10/377,743 patent/US20030171438A1/en not_active Abandoned
-
2004
- 2004-11-23 US US10/994,364 patent/US7396946B2/en not_active Expired - Fee Related
-
2008
- 2008-06-24 JP JP2008164252A patent/JP5052423B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-03 AR ARP090104665A patent/AR074465A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323908B1 (no) | Anvendelse av en prostaglandinlignende forbindelse til fremstilling av et farmasoytisk preparat for behandling av utvortes sekresjonsforstyrrelser, samt forbindelsen 11-dehydroksy-13,14-dihydro-15-keto-16,16-difluor-PGE1 | |
| US8530519B2 (en) | Method for promoting upper gastrointestinal bicarbonate secretion | |
| US8889735B2 (en) | Method for treating asthenopia | |
| MX2008011148A (es) | Metodo y composicion para tratar enfermedad pulmonar obstructiva cronica. | |
| WO2003011299A2 (en) | Treatment of ocular hypertension and glaucoma | |
| US20080207759A1 (en) | Method for protecting mitochondria | |
| JPH05504962A (ja) | 眼圧低下剤としてのプロスタグランジンＦ↓３αの使用 | |
| US20040254247A1 (en) | Method and composition for treatnment of ocular hypertension and glaucoma | |
| AU2002355693A1 (en) | Treatment of ocular hypertension and glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |